Psoriatic Arthritis + GLP-1 Medication Research
Remember to ALWAYS speak with your doctor, as this is not medical advice, just research!
How to use this page:
Download the PDF I have created below OR
Read the information below that’s included in the PDF if you don’t want to download it.
GLP-1 Receptor Agonists in Psoriatic Disease
Immune Mechanisms, Inflammatory Pathway Evidence, and Clinical Implications
GLP-1 receptor agonists (GLP-1 RAs) — including semaglutide, liraglutide, tirzepatide, exenatide, and dulaglutide — demonstrate significant anti-inflammatory activity in psoriatic arthritis (PsA) and psoriasis (PsO) through at least five distinct immune mechanisms: NF-κB pathway inhibition, AMPK activation, suppression of the IL-23/Th17 axis, modulation of iNKT cells, and reduction of dermal gamma-delta T cells. These effects occur independently of glucose regulation or metabolic changes, positioning GLP-1 RAs as potential immune-modulating adjuncts in PsA management. Evidence ranges from well-characterised preclinical mechanisms to early-phase RCTs and large observational datasets.
1. Background: The Inflammatory Landscape of Psoriatic Disease
Psoriatic arthritis (PsA) is a chronic systemic inflammatory condition classified within the psoriatic disease (PsD) spectrum. The immunopathology is driven primarily by activation of Th1 and Th17 lymphocyte pathways, resulting in elevated concentrations of TNF, IFN-γ, IL-17, IL-22, and IL-23 in both skin and synovial tissues. This cytokine milieu promotes joint erosion, enthesitis, and the proatherogenic endothelial damage that accounts for the substantially elevated cardiovascular risk observed in this population.
Current biologic therapies target individual cytokines — TNF inhibitors, IL-17A inhibitors, IL-23 inhibitors — but leave the broader inflammatory dysregulation partially unaddressed. The emerging evidence reviewed here suggests GLP-1 RAs may act on upstream regulatory nodes, potentially complementing existing targeted therapies.
Key references: Buonanno et al., Inflamm Res 2025; Karacabeyli & Lacaille, Nat Rev Rheumatol 2025; Karmacharya et al., Arthritis Care Res 2024
2. Immune Mechanisms: How GLP-1 RAs Modulate Inflammation
Five interconnected immune mechanisms have been identified across preclinical experiments, translational studies, and clinical observations. These are described below with supporting evidence and, where available, effect size data.
2.1 NF-κB Pathway Inhibition
The nuclear factor kappa B (NF-κB) transcription factor family is a central regulator of inflammatory gene expression. When activated — by TNF, lipopolysaccharide, or other danger signals — NF-κB drives transcription of pro-inflammatory cytokines including IL-1, IL-6, IL-12, IL-23, and TNF itself, creating a self-amplifying inflammatory loop particularly relevant to PsA pathogenesis.
GLP-1 RAs interrupt this loop via two mechanistic branches:
- AMPK-mediated pathway (psoriasis keratinocytes): GLP-1 receptor activation phosphorylates AMP-activated protein kinase (AMPK), which activates sirtuin-1 deacetylase. Sirtuin-1 deacetylates the RelA/p65 subunit of NF-κB, preventing its nuclear translocation. This mechanism was characterised in keratinocyte models and correlates with reduced PASI scores in clinical observations.
- IκBα phosphorylation block (synoviocytes): In fibroblast-like synoviocytes — the key effector cells of joint inflammation — GLP-1 RAs prevent phosphorylation of IκBα. Normally, phosphorylated IκBα is degraded, freeing NF-κB to enter the nucleus. By blocking this step, GLP-1 RAs halt NF-κB nuclear translocation entirely. Documented with lixisenatide, exenatide, and dulaglutide.
Downstream consequences include reduced gene expression for TNF-α, IL-6, IL-8, IL-1β, MCP-1, and HMGB-1 — all elevated in PsA synovium.
Sources: NCT07251556 trial rationale; Buonanno et al. 2025; Karacabeyli & Lacaille, Nat Rev Rheumatol 2025
2.2 IL-23 / Th17 Axis Suppression
The IL-23/Th17 pathway is central to PsA pathogenesis and targeted by several approved biologics (guselkumab, risankizumab, secukinumab, ixekizumab). IL-23 drives differentiation of Th17 cells, which secrete IL-17A and IL-22 — key drivers of joint inflammation and skin plaques.
GLP-1 RAs suppress this axis at multiple levels. Evidence documents reductions in IL-17, IL-22, and IL-23. Mechanistically, this occurs through downstream NF-κB suppression (IL-23 is an NF-κB target gene) and direct effects on gamma-delta T cells and JAK/STAT signalling, including modulation of STAT3 and SOCS3.
Sources: Buonanno et al., Inflamm Res 2025; Medscape 'Targeting the Triad' 2025; Dermatology Times 2025
2.3 Gamma-Delta (γδ) T Cell Reduction and IL-17 Suppression
Dermal γδ T cells are an important source of IL-17 in psoriatic skin, stimulated by IL-23. In a prospective case series by Buysschaert et al. (n=7, exenatide or liraglutide over 20 weeks), dermal γδ T cells in skin biopsies fell from 5.9 ± 4.6% to 2.9 ± 3.5% — a reduction correlated with improved PASI scores and reduced IL-17 mRNA expression.
Sources: Buysschaert et al., Br J Dermatol 2014; PMC12339632
2.4 Invariant Natural Killer T (iNKT) Cell Redistribution
iNKT cells accumulate in psoriatic lesions and amplify local inflammation. GLP-1 RAs appear to redistribute these cells away from inflammatory tissue. Sullivan et al. (n=7, liraglutide 1.2 mg/day, 10 weeks) documented circulating iNKT cells rising from 0.13% to 0.40% of T lymphocytes (p=0.03), accompanied by PASI reduction from 4.8 to 3.0 (p=0.03) and DLQI reduction from 6.0 to 2.0 (p=0.03). GLP-1 RA-induced iNKT cytokine secretion inhibition was dose-dependent without affecting cytolytic degranulation — suggesting immune modulation rather than suppression.
Sources: Sullivan et al., Br J Dermatol 2012; Buonanno et al. 2025
2.5 Synoviocyte Protection and Matrix Metalloproteinase Suppression
In fibroblast-like synoviocytes (FLS) — primary mediators of joint erosion — GLP-1 RAs (lixisenatide, exenatide, dulaglutide) demonstrated three protective effects in preclinical experiments:
- Cytokine suppression: Reduction in TNF, IL-6, IL-8, IL-1β, MCP-1, and HMGB-1 via NF-κB inhibition.
- Oxidative stress reduction: Enhanced mitochondrial function and attenuated reactive oxygen species (ROS), protecting against cellular damage characteristic of chronic synovitis.
- MMP suppression: Inhibition of MMP-3 and MMP-13 — the enzymes primarily responsible for cartilage degradation — with direct structural implications for joint preservation.
Sources: Buonanno et al. 2025; Karacabeyli & Lacaille, Nat Rev Rheumatol 2025
3. Mechanism Comparison Table
The table below maps each identified immune mechanism to the drug(s) studied, evidence type, key outcomes, and evidence strength rating. Ratings follow a modified Oxford CEBM framework adapted for early-phase immunology evidence.
| Mechanism | Drug(s) | Study Type | Key Finding | Target Cytokines / Cells | Evidence |
|---|---|---|---|---|---|
| NF-κB inhibition via AMPK (keratinocytes) | Liraglutide, exenatide | Preclinical + case series | AMPK phosphorylation → sirtuin-1 → RelA deacetylation → NF-κB blocked | TNF-α, IL-6, IL-8, IL-1β, NF-κB p65, STAT3 | Moderate |
| NF-κB inhibition via IκBα block (synoviocytes) | Lixisenatide, exenatide, dulaglutide | Preclinical (FLS models) | Prevents IκBα phosphorylation → halts NF-κB nuclear translocation → cytokine gene suppression | TNF, IL-6, IL-8, IL-1β, MCP-1, HMGB-1 | Moderate |
| IL-23 / Th17 axis suppression | Class effect (multiple GLP-1 RAs) | Preclinical + observational | Reduction in IL-17, IL-22, IL-23; JAK/STAT3/SOCS3 modulation | IL-17A, IL-22, IL-23, STAT3, SOCS3 | Low–Moderate |
| Dermal γδ T cell reduction | Exenatide, liraglutide | Prospective case series (n=7) | γδ T cells in biopsies: 5.9% → 2.9% (p<0.05) over 20 wks; correlated with PASI improvement | IL-17 (via γδ T cells), IL-23 | Low |
| iNKT cell redistribution | Liraglutide, exenatide | Prospective cohort + in vitro | Circulating iNKT cells: 0.13% → 0.40%; plaque iNKT reduced; PASI and DLQI improved | iNKT-derived cytokines, IL-10 (anti-inflammatory increase) | Low |
| MMP suppression / chondroprotection | Lixisenatide, exenatide, dulaglutide | Preclinical (FLS) | MMP-3 and MMP-13 inhibited; mitochondrial function enhanced; ROS reduced | MMP-3, MMP-13, ROS | Low |
| TNF-α signalling inhibition | Class effect | Preclinical + observational | GLP-1 RAs inhibit NF-κB downstream of TNF receptor activation; reduced TNF-producing monocytes | TNF-α, downstream NF-κB | Low–Moderate |
4. Study Summaries
5. Evidence Strength Ratings by Domain
Ratings synthesise evidence quality across mechanistic domains using a modified framework for early-phase translational immunology.
| Evidence Domain | Rating | Basis | Key Gap |
|---|---|---|---|
| NF-κB pathway inhibition (molecular mechanism) | MODERATE | Replicated across 3+ preclinical models; AMPK branch confirmed mechanistically; cited in Phase 4 trial rationale | No direct NF-κB measurement in PsA RCT |
| IL-23 / Th17 / IL-17 suppression | LOW–MODERATE | Consistent across observational data; γδ T cell reduction measured in biopsies; correlates with PASI | No controlled IL-17 quantification in PsA-specific study |
| iNKT cell redistribution | LOW | Single prospective cohort (n=7); directionally consistent with mechanism; p-values reported | Very small n; no replication in PsA; no placebo control |
| Synoviocyte protection / MMP suppression | LOW (Preclinical) | Three independent FLS experiments; consistent findings; mechanistically plausible | No in vivo or clinical confirmation in PsA |
| Clinical joint response (ACR50) — combination therapy | MODERATE | Phase 3b RCT (TOGETHER-PsA, n=271); ACR50 statistically superior in combination arm | Open-label; mechanism not directly measured; no GLP-1 monotherapy arm |
| Cardiovascular / MACE reduction in PsA | MODERATE | Large retrospective cohort (TriNetX database); consistent with SELECT trial data | Retrospective design; confounding by indication possible |
| GLP-1 RA as PsA monotherapy / primary anti-inflammatory | INSUFFICIENT | No RCT data for GLP-1 monotherapy in PsA with inflammation as primary outcome | NCT07251556 ongoing; results needed |
6. Active Clinical Trials
| Trial ID / Name | Drug | Population | Primary Outcome | Status |
|---|---|---|---|---|
| NCT06588296 TOGETHER-PsA |
Tirzepatide + ixekizumab | PsA + overweight/obesity, n=279 | ACR50 + ≥10% weight reduction at week 36 | Published 2026 |
| NCT07251556 | Semaglutide (up to 1.0 mg/wk) | Non-diabetic PsA, n=40 | CIMT (subclinical atherosclerosis); MDA; DAPSA | Not yet recruiting |
| NCT07111494 | GLP-1 RA vs. nutrition intervention | Obese PsA + T2DM | DAPSA remission at 12 and 24 weeks | Recruiting |
| NCT06937060 SEMPSO |
Semaglutide (up to 2.0 mg/wk) | Psoriasis + obesity, n=14 | PASI, DLQI, systemic inflammation at 24 wks | Recruiting |
7. Implications for PsA Treatment
7.1 Complementary Mechanism to Existing Biologics
Current PsA biologics target individual cytokines downstream of the inflammatory cascade. GLP-1 RAs appear to act upstream at the NF-κB regulatory node, potentially reducing the amplitude of the entire inflammatory response rather than blocking a single effector. This mechanistic complementarity is the biological rationale for the combination approach tested in TOGETHER-PsA, and may explain why combination therapy yielded ACR50 improvement beyond what biologics alone achieve.
7.2 The Weight-Independent Anti-Inflammatory Question
A critical and partially unresolved question is whether anti-inflammatory effects are attributable to GLP-1 RA immune mechanisms directly, or mediated through adipose tissue reduction. NCT07251556 — testing semaglutide in non-diabetic PsA patients and tracking inflammatory markers alongside vascular outcomes — is specifically designed to address this. The preclinical FLS evidence and iNKT cell redistribution data provide mechanistic support for weight-independent effects, but human RCT confirmation is lacking.
7.3 Cardiovascular Risk Reduction as a Co-benefit
PsA patients carry a 43% higher risk of major cardiovascular events compared to the general population, attributable to both systemic inflammation and traditional CV risk factors. The ACR 2025 retrospective data showing lower MACE in GLP-1 RA users is clinically significant independent of whether joint outcomes improve. This aligns with the SELECT trial (semaglutide in non-diabetic patients with CVD), which demonstrated CV event reduction via mechanisms including direct anti-inflammatory vascular effects.
7.4 Limitations and Cautions
- Most human immune-mechanism data derives from psoriasis (PsO) studies, not PsA specifically. Extrapolation is biologically plausible but not validated.
- Small sample sizes dominate clinical immune-cell studies (n=7 in key iNKT and γδ T cell studies), limiting statistical power and generalisability.
- No RCT has assessed GLP-1 RA monotherapy with joint inflammation as a primary endpoint in PsA.
- TOGETHER-PsA is open-label, and the combination arm cannot isolate tirzepatide's contribution from ixekizumab's established efficacy.
- Mechanistic studies were performed with older GLP-1 RAs (liraglutide, exenatide). Extrapolation to semaglutide and tirzepatide is pharmacologically reasonable but not yet directly confirmed for all pathways.
8. References
- Merola JF, Mease P, Kivitz A et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with PsA and overweight or obesity (TOGETHER-PsA). Arthritis Rheumatol. 2026 Mar 28. View study → ClinicalTrials NCT06588296 →
- Haberman RH, Rice AL, Chen K, Scher U, Thib S, Scher JU, Eder L. GLP-1 receptor agonist therapy is associated with improvement in psoriatic arthritis-related and metabolic outcomes: a retrospective analysis of two cohorts. Arthritis Rheumatol. 2026 Apr 6. View study →
- Buonanno S, Gaggiano C, Terribili R, Cantarini L, Frediani B, Gentileschi S. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflamm Res. 2025;74(1):167. Open Access View full text (free) → PubMed →
- Karacabeyli D, Lacaille D. Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions. Nat Rev Rheumatol. 2025;21(11):671-683. View abstract → PubMed →
- Karmacharya P et al. GLP-1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review. J Clin Rheumatol. 2024;30(1):26-31. PubMed →
- Sullivan PW et al. GLP-1 analogue therapy for psoriasis with iNKT cell analysis: prospective cohort (n=7). Br J Dermatol. 2012. PubMed →
- Buysschaert M et al. Improvement of psoriasis during GLP-1 analogue therapy associated with decreased dermal gamma-delta T-cell number. Br J Dermatol. 2014;171(1):155-161. PubMed →
- Xu X et al. GLP-1 receptor agonist impairs keratinocyte inflammatory signals by activating AMPK. Exp Mol Pathol. 2019;107:124-128. PubMed →
- Tsibadze N, Tskhakaia I, Tan I. Mortality and major adverse cardiac events (MACE) with GLP-1 receptor agonists in psoriatic arthritis. Abstract #0849. Arthritis Rheumatol. 2025;77(suppl 9). ACR Convergence 2025. View abstract → ACR press release →
- NCT06588296 — TOGETHER-PsA: Ixekizumab + tirzepatide in PsA with obesity/overweight. Phase 3b. Sponsor: Eli Lilly. ClinicalTrials.gov → Lilly press release →
- NCT07251556 — Semaglutide in non-diabetic PsA: subclinical atherosclerosis, MDA, DAPSA. Phase 4. Sponsor: Chinese University of Hong Kong. ClinicalTrials.gov →
- NCT07111494 — GLP-1 vs. nutrition counselling in obese PsA with T2DM. Primary outcome: DAPSA remission. ClinicalTrials.gov →
- NCT06937060 (SEMPSO) — Semaglutide in psoriasis and obesity. Phase 3. Sponsor: University of Hong Kong. ClinicalTrials.gov →
- Haran K et al. Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. Psoriasis (Auckl). 2024;14:143-152. PubMed →
- GLP-1RAs in patients with psoriasis — PMC review. 2025. Open Access View full text (free) →
- Medscape. Targeting the triad: GLP-1 receptor agonists, obesity, psoriasis, and psoriatic arthritis — 5 things to know. August 2025. View article →